Key Takeaways
- “Genetic test” is not one product. A germline test may investigate inherited risk; a tumor test looks mainly for acquired changes that may guide cancer care; a diagnostic test may address a suspected rare disease, carrier status or another defined question.
- The specimen matters. Germline testing commonly uses blood or saliva, while tumor profiling uses cancer tissue or circulating tumor DNA. A change found in a tumor is not automatically inherited.
- A positive result needs clinical interpretation. A negative result may be a true negative, an uninformative negative or a limitation of the method and genes tested.
- A variant of uncertain significance, or VUS, usually should not drive irreversible surgery or a major treatment decision. Its meaning may change as evidence accumulates.
- Bigger panels are not automatically better. They can increase uncertain and secondary findings without improving the answer to the patient’s actual question.
- Before testing, clarify the purpose, specimen, laboratory method, detectable variant types, important blind spots, consent choices, family implications and who will re-contact the patient if interpretation changes.
Content
A patient may be offered “genetic testing” by an oncologist, a fertility clinic, a neurologist, an online company or a hospital abroad. The label sounds precise, but these tests can answer very different questions. Ordering first and defining the question later is how people end up with an expensive report that neither confirms a diagnosis nor changes care.
The useful starting sentence is: “We are ordering this test to find out whether…” If the clinician, laboratory and patient cannot finish that sentence in the same way, the test is not ready to be ordered.
Three testing lanes that should not be mixed
1. Germline testing: could this change be inherited?
Germline variants are present from conception and can be found in non-tumor cells. Testing often uses blood or saliva. In cancer care, the question may be whether a person has an inherited cancer-predisposition syndrome. In other specialties, it may help diagnose a genetic disorder or identify carrier status.
NCI emphasizes an important distinction: cancer is a genetic disease because cancers arise through DNA changes, but most cancers are not caused by an inherited change [1]. A confirmed germline result can affect the patient and biological relatives, so pre- and post-test genetic counseling is especially valuable when the result could change surveillance, preventive surgery or family testing [2].
2. Tumor or somatic profiling: what is happening in this cancer?
Tumor profiling examines alterations in cancer cells. Its purpose may be to classify the tumor, find a treatment-associated biomarker, assess eligibility for a clinical trial or investigate resistance. The specimen may be archived tissue, a new biopsy or circulating tumor DNA from blood.
These findings can change over time and may vary between parts of a tumor. NCI notes that a sample can be insufficient and that not every cancer cell necessarily carries the same biomarkers [3]. A matched biomarker also does not guarantee that a drug will work.
Occasionally, tumor testing detects a change that could be germline. That is a clue, not proof. Confirmation normally requires testing a non-tumor sample through an appropriate germline pathway [1]. Conversely, a negative tumor panel does not exclude an inherited syndrome when the personal or family history remains suspicious.
3. Diagnostic or predictive testing: what exact clinical question is being tested?
Outside oncology, testing may look for the cause of developmental delay, cardiomyopathy, a neurological condition, hearing loss or another suspected disorder. Other tests address reproductive carrier status, prenatal questions or a drug-response marker. Each has a different target population, evidence base and consent discussion.
The word “genomic” often describes analysis across many genes or large sections of DNA, while “genetic” is broader everyday language. Neither word tells you whether the test is clinically appropriate. Ask for the actual test name and scope.
Define the test before giving the sample
Put the following details in writing:
- the clinical question and what decisions could change;
- whether the sample is tumor, blood, saliva, cultured cells or another material;
- the genes and regions examined, including relevant transcripts;
- whether the method can detect single-letter changes, small insertions/deletions, copy-number changes, structural rearrangements, repeat expansions, methylation changes or mosaicism;
- minimum tissue, tumor-content and quality requirements;
- analytical limitations and whether important regions have poor coverage;
- expected turnaround time and what happens if the sample fails;
- whether a positive tumor finding needs germline confirmation;
- whether secondary findings will be sought or reported;
- who interprets the result and whether genetic counseling is included;
- where the sample and data will be stored, for how long, and whether research use or re-contact is optional;
- the full price, including confirmatory testing and family testing.
This list is not administrative decoration. A sequencing panel may be excellent at detecting some changes and unable to detect another category that is central to the suspected condition.
A broader panel creates more information—and more ambiguity
When several disorders look alike, a multigene panel can be efficient. But adding genes with weak or irrelevant clinical evidence can produce more VUS results and incidental findings. It can also make consent harder because the report may reveal risks unrelated to the original reason for testing.
MedlinePlus describes secondary findings as medically relevant results unrelated to the primary testing indication [5]. Patients should know before testing whether the laboratory actively looks for such findings, whether they may opt out, and how results would be confirmed.
Choose breadth because it fits the clinical differential diagnosis, not because a marketing page counts more genes.
Read the result category before reading the disease name
Laboratories commonly classify germline variants as pathogenic, likely pathogenic, uncertain, likely benign or benign. The exact report and clinical context still matter.
Pathogenic or likely pathogenic does not always predict whether, when or how severely a condition will occur. Penetrance, age, sex, family history and other factors can modify risk. A positive carrier result is also different from a diagnosis.
VUS means current evidence cannot determine whether the change causes disease. NCI states that a VUS usually should not be used to make healthcare decisions and that most are ultimately reclassified as benign [2]. Do not translate “uncertain” into “dangerous.” Ask what evidence could resolve it and who will review future reclassification.
Negative has several meanings. If a known familial pathogenic variant was specifically tested and not found, the result may be a true negative for that familial change. If no family cause is known, a negative panel may be uninformative: the condition may involve a gene not tested, a type of variant the method misses, or a cause not yet understood. MedlinePlus cautions that a negative result cannot always rule out a disorder because tests do not detect every disease-causing alteration [4].
For tumor profiling, also examine variant allele fraction, sample purity, assay sensitivity, quality flags and whether the report distinguishes a detected alteration from a clinically actionable one.
What a clinically usable report should contain
A report should let another qualified team understand what was tested and what was not. Look for:
- patient and specimen identifiers, collection date and specimen type;
- test name, laboratory and report version;
- method, genes/regions, reference sequence and important coverage limits;
- variant notation and classification;
- evidence supporting the interpretation;
- tumor percentage and allele fraction where relevant;
- quality or assay-failure warnings;
- clinical interpretation and recommended confirmation;
- date, responsible professional and amendment history.
A one-page result that lists “high risk” without methods, variants or limitations is difficult to audit across hospitals.
Direct-to-consumer results need a clinical bridge
Consumer tests can be useful for curiosity or as a prompt for a clinical conversation, but different companies examine different sets of variants. FDA explains that a negative direct-to-consumer result does not necessarily mean no risk and advises against making medical decisions solely from such a result [6]. Raw-data interpretations from third-party websites add another layer of possible error.
If a result could change screening, medication, pregnancy planning or surgery, take the original laboratory report—not a screenshot—to a clinician or genetic counselor. Confirm the finding in a clinical laboratory when appropriate.
Cross-border testing adds handoff questions
Before a sample leaves the country or moves between hospitals, confirm acceptable collection tubes, temperature, transit time, customs documents, sample ownership and the return format for raw and interpreted data. Ask whether the destination team can review the full report and whether the home team can act on it.
Clinical laboratories should operate under defined quality-management and reporting systems. China’s National Health Commission, for example, places clinical gene-amplification testing within formal laboratory-management requirements [7]. Accreditation or regulation does not make every panel suitable for every patient; appropriateness still begins with the clinical question.
A sensible final check
Before paying, the patient should be able to answer six questions in plain language: What question is this test answering? Whose DNA is being tested? What can the method miss? What decisions could each result change? Could the result matter to relatives? Who will explain and revisit it?
If one of those answers is “we will know after the report arrives,” pause. Genetic information can be valuable for years, but only when its purpose, limitations and responsibilities are clear from the start.
FAQ
1. Does a mutation found in my tumor mean my children inherited it?
Not necessarily. Most tumor alterations are somatic and are confined to the cancer. Some findings raise suspicion for a germline variant, but confirmation generally requires a separate non-tumor sample and appropriate genetic counseling [1].
2. Should a VUS change surgery or treatment?
Usually no. A VUS is not established as disease-causing and generally should not support an irreversible medical decision [2]. Management should rely on the diagnosis, personal and family history, established biomarkers and other clinical evidence while the variant is periodically re-evaluated.
3. Does a negative genetic test rule out inherited risk?
It depends. A true negative for a known familial variant is informative. A negative panel in a family without a known cause may not exclude inherited risk because the relevant gene, variant type or current scientific knowledge may be incomplete [4].
4. Is the panel with the most genes always the best value?
No. The best panel covers genes and variant types relevant to the clinical question with validated methods. Unnecessarily broad testing can add uncertain or secondary findings without improving the decision.
5. Can I use a home DNA result to choose a drug or preventive operation?
Do not act on it alone. Review the original result with a qualified clinician or genetic counselor and obtain clinical confirmation when the finding could change care. Consumer tests vary in scope and a negative result can miss relevant variants [6].
Sources
- National Cancer Institute — The Genetics of Cancer
- National Cancer Institute — Genetic Testing for Inherited Cancer Risk
- National Cancer Institute — Biomarker Testing for Cancer Treatment
- MedlinePlus Genetics — What Do the Results of Genetic Tests Mean?
- MedlinePlus Genetics — What Are Secondary Findings from Genetic Testing?
- U.S. Food and Drug Administration — Direct-to-Consumer Tests
- National Health Commission of the People’s Republic of China — Response on Clinical Genetic Testing Laboratory Management